Dr. Sascha Gick and Dr. Steffen Heck of St. Vinzenz-Hospital Koln Awarded for Outstanding Scientific Achievements With IlluminOss' Photodynamic Bone Stabilization System
EAST PROVIDENCE, RI and BERLIN, GERMANY--(Marketwired - Oct 30, 2014) - IlluminOss Medical, a commercial stage medical device company focused on minimally invasive orthopedic fracture repair, today announced that Dr. Sascha Gick and Dr. Steffen Heck of St. Vinzenz-Hospital Köln, Academic Teaching Hospital affiliated to the University of Cologne, have been awarded the prestigious Deutsche Gesellschaft für Unfallchirurgie (DGU) Prize for Innovation 2014 for their use of IlluminOss' Photodynamic Bone Stabilization System. Doctors Gick and Heck, senior surgeons in the Department for Trauma, Orthopaedics, Hand and Reconstructive Surgery headed by chief physician Prof. Dietmar Pennig, have achieved significant advantages in the treatment of complex fracture situations with the use of IlluminOss technology, the world's first and only photodynamic fracture repair and stabilization system.
Gick and Heck received the recognition for their "Photodynamic Polymer for Stabilization of Fractures" submission at the German Congress of Orthopaedics and Traumatology (DKOU). The Innovation Award highlights technical innovations that are being incorporated into patient care, and is awarded annually for the outstanding work of surgeons from Germany and abroad.
"IlluminOss is pleased to have partnered with the team at St. Vinzenz for the past several years, where the Department for Trauma, Orthopaedics, Hand and Reconstructive surgery has been renowned for pioneering the introduction of novel technologies in external fixation and intramedullary stabilization for the past twenty+ years," said Robert Rabiner, the president & founder of IlluminOss Medical. "We extend our congratulations to Dr. Gick and Dr. Heck and the rest of the trauma department under the direction of Prof. Pennig on this well-deserved achievement and look forward to seeing the results of their continued application of our system."
IlluminOss' Photodynamic Bone Stabilization System is a minimally invasive procedure that incorporates the use of a thin walled PET balloon, that is infused with a liquid monomer, inserted into the intramedullary canal conforming to the shape of the patient's specific anatomy. The device forms as an implant once the surgeon activates the visible light within the PET balloon. Once cured, the implant provides longitudinal strength and rotational stability over the length of the implant and may decrease procedure, recovery, and healing time. IlluminOss' Photodynamic Bone Stabilization System is commercially available and has been approved for clinical applications in international countries under a CE Mark since 2010, making it one of the most proven products to be honored at DKOU this year.
"Our team is always looking to elevate the level of care we are able to provide our patients by incorporating the latest and best technologies in their treatments," said Prof. Dr. Dietmar Pennig. "IlluminOss' bone stabilization technology has proven to be a true innovation, bringing significant advantages to the treatment of complex fracture situations with osteopenia, as well as peri-implant fractures and metastatic bone disease."
IlluminOss Medical is a privately-held, commercial stage medical device company focused on designing, developing and marketing orthopedic fracture repair products that leverage its proprietary bone stabilization technology, Photodynamic Bone Stabilization System (PBSS). This minimally invasive technology allows for fracture fixation through patient specific intramedullary implants. The PBSS System utilizes a light-curable polymer, contained within an expandable balloon catheter, to achieve bone stabilization. The revolutionary procedure is made through a small percutaneous surgical approach providing patients and clinicians with a fast, patient-specific, method of orthopedic bone stabilization. The company currently markets its products in international countries under a CE Mark for approved clinical applications through both a direct sales force and distribution networks. Founded in 2007, IlluminOss is headquartered in East Providence, RI, and funded by Foundation Medical Partners, New Leaf Venture Partners, Tekla Capital, Life Sciences Partners, SR One, Longwood Fund, Excel Venture Management, Pappas Ventures, Mieza Capital and Slater Technology. Learn more at www.illuminoss.com.
The IlluminOss products are Investigational Devices; limited by Federal law to Investigational Use and are not approved for sale in the USA.
SVM Public Relations